Stockreport

Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patientsSPARE Model is up to 40-50% more accurate than stan [Read more]